Datasheet | Title | Summary |
| Invenra’s Rapid Antibody Expression Services provide a full-service, 8-week solution for producing high-purity monoclonal and B-Body bispecific antibodies at various scales, ranging from high-throughput 96-well screening plates to 500 mL validation batches. | |
| Invenra’s Rapid Antibody Discovery Services utilize a high-throughput, streamlined workflow and proprietary phage display technology to deliver high-quality monoclonal and bispecific antibody leads in industry-leading timelines. | |
| The B-Body® Bispecific Platform is a premier bispecific antibody framework engineered on a human IgG-like scaffold to provide industry-leading yields (6–11 g/L), high solubility, and low viscosity, enabling efficient manufacturing and subcutaneous delivery | |
| Invenra’s T-Body™ Trispecific Antibody Platform utilizes an innovative IgG-like structure with three Fab arms and proprietary CH3 domain pairs to enable the simultaneous targeting of three distinct antigens, delivering robust expression yields (exceeding 100μg/mL) and high purity through efficient, modular assembly. |
Invenra Literature Library
Slide Deck | Title | Summary | Event & Speaker |
| This presentation describes Invenra’s B-Body® Bispecific and T-Body™ Trispecific Antibody Platforms and a 12x12 matrix screening strategy that rapidly identifies and validates multispecific ADC candidates with superior cytotoxic activity across heterogeneous breast cancer models. | 16th Annual World ADC Nov 4, 2025 Bonnie Hammer, PhD | |
| This presentation introduces Invenra’s T-Body™ Trispecific and B-Body® Bispecific Antibody Platforms, highlighting their robust manufacturability, IgG-like properties, and rapid 12x12 matrix screening workflow to accelerate and de-risk multispecific ADC discovery and development. | Antibody Engineering & Therapeutics Dec 16, 2025 Nicholas Marshall, PhD |
Poster | Title | Summary | Event & Authors |
| Antibody Engineering & Therapeutics Dec 16, 2025 Belinda Wenke, Ron Jacak, Mark Bercher, Jessica Wiwczar, Justin Wetter, Joseph Gawdzick, Laura Franz, Nicholas Marshall, and Bonnie Hammer, | ||
| Antibody Engineering & Therapeutics Dec 16, 2025 Belinda Wenke, Jessica Wiwczar, Jeremy Woodall, Jadan Norman, Joe Gawdzik, Justin Wetter, Paul Guyett, Dileep Pulukkunat, Nicholas Marshall and Bonnie Hammer |
White Paper | Title | Summary |
| This white paper demonstrates that Invenra’s B-Body® and T-Body™ modular multispecific antibody platforms enable plug-and-play assembly and format-agnostic purification to deliver consistently high-purity bispecific and trispecific antibodies across diverse architectures without molecule-specific optimization, thereby accelerating and de-risking development from discovery to manufacturing. |